Investigators from the Dana-Farber Cancer Institute (Boston, MA, USA) have identified the serum-based protein angiopoietin-2 (ANGPT2) as a prognostic biomarker that could be utilized to predict clinical outcomes with patients with advanced melanoma and could identify those patients that might respond to immune checkpoint therapy.
Publications
Australian Clinical Study Published in British Journal of Dermatology Presents Further Benefits With Nevisense
The Australian study previously presented at the World Congress of Cancers of the Skin showing that Nevisense can detect malignant melanoma three months earlier in follow-up cases and reduce the need for follow-up by nearly half, has now been published in the British Journal of Dermatology (BJD).
Cause of rare acral and mucosal melanomas not linked to sun exposure, study finds
Australian scientists have discovered that the danger of melanoma is not just related to sun exposure.
Shining a light on melanomas that aren’t caused by the sun
‘Slip, slop, slap’ is synonymous with being Australian and playing it safe in the sun. These sun smart rules reduce our chances of getting melanoma of the skin. However, new research tells a different story for those affected by rarer forms of melanoma.